Subject & Formulation
Reset
Magnesium Chemical Form
Magnesium Bisglycinate (Chelate - High Bioavailability)
Magnesium L-Threonate (Synaptic / BBB Permeant)
Magnesium Citrate (Organic Salt - Rapid Absorption)
Magnesium Malate (Krebs Cycle Intermediate)
Magnesium Taurate (Cardiovascular & GABAergic)
Magnesium Oxide (Inorganic Salt - Low Bioavailability)
Elemental Mg Dose (Supplement)
200 mg
Baseline Dietary Mg Intake
210 mg/day (RDA: 320-420mg)
Target Clinical Indication
Sleep Latency & Slow-Wave Sleep Duration
Migraine Frequency & Cortical Spreading Depression
Somatic Tension & NMDA-GABA Balance
Gastrointestinal Sensitivity
Low (Tolerates osmotic load well)
Moderate (Standard threshold)
High (Prone to loose stools >180mg unabsorbed)
Within Safe Tolerable Limits
Supplement elemental dose is below the 350 mg/day non-food Tolerable Upper Intake Level (UL).
24-Hour Pharmacokinetic & CNS Ionized Mg²⁺ Flux
Tmax: 2.2h | Cmax: 1.08 mmol/L
Estimated Bioavailability
23.5%
Intestinal uptake
Total Daily Elemental
410 mg
Diet + Supplement
Unabsorbed Osmotic Load
153 mg
Risk: Low
Predicted Clinical Delta
-16.2 min
Sleep latency reduction
NEUROLOGICAL PATHWAY ENGAGEMENT
CSF Penetration Moderate-High
Odds Ratio Likely Responder
Clinical Trial Meta-Synthesis:
Subject baseline is deficient (<320 mg/day). Magnesium Bisglycinate delivers superior fractional chelated absorption with intact dipeptide transport (PEPT1), yielding an expected sleep latency reduction of ~16.2 minutes with negligible gastrointestinal laxative risk.